Mark Smith, Finch Therapeutics CEO

Take­da breaks off five-year pact with mi­cro­bio­me part­ner, hand­ing back two pre­clin­i­cal drugs

When Take­da first part­nered up with Finch Ther­a­peu­tics in 2017, the Japan­ese phar­ma put on the map what was still a very ear­ly-stage mi­cro­bio­me play­er aim­ing to cap­i­tal­ize on the idea that you could reap the ben­e­fits of fe­cal trans­plants with an oral pill — and its pre­clin­i­cal pro­gram for in­flam­ma­to­ry bow­el dis­ease.

Over the next few years, Take­da re­jigged the al­liance a few times, get­ting its hands on a sec­ond drug, tak­ing more re­spon­si­bil­i­ty for de­vel­op­ment and man­u­fac­tur­ing, and lat­er tap­ping Finch to con­duct more fea­si­bil­i­ty work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.